|
|
Volumn 374, Issue 12, 2016, Pages 1197-1198
|
|
Targeted therapy alone for acute promyelocytic Leukemia
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTILEUKEMIC AGENT;
ARSENIC TRIOXIDE;
GEMTUZUMAB OZOGAMICIN;
LIVER ENZYME;
RETINOIC ACID;
ANTINEOPLASTIC AGENT;
ORGANOARSENIC DERIVATIVE;
OXIDE;
ADVERSE DRUG REACTION;
CANCER COMBINATION CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER MORTALITY;
CANCER PATIENT;
CANCER RISK;
CANCER SURVIVAL;
DRUG EFFICACY;
DRUG SAFETY;
EVENT FREE SURVIVAL;
HUMAN;
INFECTION RISK;
LETTER;
LEUKEMIA RELAPSE;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PRIORITY JOURNAL;
PROMYELOCYTIC LEUKEMIA;
QT PROLONGATION;
SECOND CANCER;
SIDE EFFECT;
SURVIVAL RATE;
SURVIVAL TIME;
TREATMENT RESPONSE;
COMPARATIVE STUDY;
DISEASE FREE SURVIVAL;
FOLLOW UP;
INTENTION TO TREAT ANALYSIS;
LEUKEMIA, PROMYELOCYTIC, ACUTE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ARSENICALS;
DISEASE-FREE SURVIVAL;
FOLLOW-UP STUDIES;
HUMANS;
INTENTION TO TREAT ANALYSIS;
LEUKEMIA, PROMYELOCYTIC, ACUTE;
OXIDES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TRETINOIN;
|
|
EID: 84962286932
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1513710 Document Type: Letter |
|
Times cited : (59)
|
|
References (3)
|
